Acumen pharmaceuticals reports first quarter 2024 financial results and business highlights

Charlottesville, va., may 14, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) (“acumen” or the “company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), today reported financial results for the first quarter of 2024 and provided a business update.
ABOS Ratings Summary
ABOS Quant Ranking